Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.

Renal cell carcinoma (RCC) continues to have a significant health impact. With the emergence of these new therapies, it is increasingly important for oncology nurses to understand the data supporting all the available choices and the adverse effects associated with each of them.

Renal cell carcinoma (RCC) continues to have a significant health impact. With the emergence of these new therapies, it is increasingly important for oncology nurses to understand the data supporting all the available choices and the adverse effects associated with each of them.

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

Join Eric Jonasch, MD and Marcia Holloway, APRN NP-C from The University of Texas MD Anderson Cancer Center as they present their expertise on a range of cases pertaining to kidney cancer.